Home pageBooks

BioWorld Top 25 Biotechnology Drugs Report


Publishing: BioWorld
Published: 2006
The BioWorld Top 25 Biotechnology Drugs Report is the first report of its kind: It delivers a comprehensive and in-depth analysis of the top 25 biotech drugs, as ranked by revenue, in one single report, and provides you with the knowledge you need to take quick action on vital business decisions related to the biotech drug market. An attempt to research this information can lead you in many different directions, but with the BioWorld Top 25 Biotechnology Drugs Report, you can access extensive profiles of each of the top 25 leading products. Analysis includes: Rank Indications Disease description & statistics Chronology of development through approval Patent protection dates Competing drugs on the market and in development Secondary indications in development Partnerships involved in the drug Projection of the drug's short-term future These drug profiles span a wide range of disease indications, including cancer, diabetes, infectious diseases, and blood disorders, and include pertinent information for many with a stake in the biotech drug market, such as biotechnology companies, pharmaceutical companies, investors, analysts, attorneys, PR firms and researchers. Chart and table-focused sections of the report also lend themselves nicely as supporting data for company reports and presentations, such as: All biotech drugs approved over the last 20 years Overall values of biotech and pharma markets Revenue generated by the top 25 biotech drugs What promising biotech drugs are on the horizon




  • BC AV CR
  • Budvar
  • CAVD
  • CZBA
  • Eco Tend
  • Envisan Gem
  • Gentrend
  • JAIP
  • Jihočeská univerzita
  • Madeta
  • Forestina